cas 2353-44-8|| where to buy 3-aminopiperidine-2,6-dione

Nom du produit:3-aminopiperidine-2,6-dione

IUPAC Name:3-aminopiperidine-2,6-dione

Unité d'emballage	Stock disponible	Prix($)
CM132080-1g	in stock	ƱƱ
CM132080-5g	in stock	ǧɅȷ
CM132080-25g	in stock	Ŵƻƻȁ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2353-44-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2353-44-8; Formule moléculaire:C5H8N2O2; Point de fusion:-; Code SMILES:NC1CCC(=O)NC1=O; Densité:

: Numéro de catalogue:CM132080; Poids moléculaire:128.13; Point d'ébullition:334.5°C at 760 mmHg; N° Mdl:MFCD11506223; Stockage:Keep in dark place, store at 2-8°C.

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: NX-2127; Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.